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Neonatal sepsis can be classiﬁed into two subtypes depending upon whether the onset of symptoms is before 72 hours of life
(early-onset neonatal sepsis—EONS) or later (late-onset neonatal sepsis—LONS). These deﬁnitions have contributed greatly to
diagnosis and treatment by identifying which microorganisms are likely to be responsible for sepsis during these periods and the
expected outcomes of infection. This paper focuses on the tools that microbiologist can oﬀer to diagnose and eventually prevent
neonatal sepsis. Here, we discuss the advantages and limitation of the blood culture, the actual gold standard for sepsis diagnosis.
In addition, we examine the utility of molecular techniques in the diagnosis and management of neonatal sepsis.
1.Introduction
Neonatal sepsis is deﬁned as a clinical syndrome of bacter-
emia with systemic signs and symptoms of infection in the
ﬁrst 4 weeks of life. When pathogenic bacteria gain access
into the bloodstream, they may cause overwhelming infec-
tion without much localization (septicemia) or may be pre-
dominantly localized to the lung (pneumonia) or the menin-
ges (meningitis).
Neonatal sepsis can be classiﬁed into two subtypes de-
pending upon whether the onset of symptoms is before 72
hours of life (early-onset neonatal sepsis—EONS) or later
(late-onset neonatal sepsis—LONS). These deﬁnitions have
contributedgreatlyto diagnosis and treatment by identifying
which microorganisms are likely to be responsible for sepsis
duringtheseperiodsandtheexpectedoutcomesofinfection.
Commonriskfactorsassociatedwiththeincreasedsever-
ity of the two syndromes are the birth weight and gestational
age. As a result of diﬀerences in clinical and microbiological
features for EONS and LONS, these syndromes will be dis-
cussed separately.
This paper is aimed to describe the main neonatal sepsis
associated pathogens and the strategies used by microbiolo-
gist to diagnose neonatal sepsis. Data shown were obtained
from a PubMed search using the following search parame-
ters: neonatal sepsis, late-onset neonatal sepsis, early-onset
neonatal sepsis, microbiological diagnosis neonatal sepsis,
molecular methods, and antibiotic resistance in neonatal
setting.
2.Early-OnsetNeonatalSepsis
Early-onset infections are caused by organisms present in the
maternalgenitaltract.Itcanoccurduetoascendinginfection
following rupture of membranes or during the passage of
the baby through infected birth canal and at the time of
resuscitation [1]. The associated factors for EONS include
low birth weight (LBW), prolonged rupture of membranes,
foul smelling liquor, multiple per vaginum examinations,
maternal fever, diﬃcult or prolonged labour, and aspiration
of meconium [2].
The most frequent microorganisms involved in EONS
are Streptococcus agalactiae (GBS), Escherichia coli,a n d
Haemophilus inﬂuenzae [3]. Very recently, a wide study
by Jean-Baptiste and coworkers reported on the possible
role of coagulase-negative staphylococci (CoNS) in neonatal
intensive care unit (NICU), but no diﬀerence in mortality
between infants with a diagnosis of deﬁnite, probable, or
possible CoNS infection was observed [4].
2.1. GBS Early-Onset Sepsis: Prevention and Diagnosis. In the
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tracts of 15 to 40% of pregnant women [5]. Approximately
half of all neonates born to GBS-colonized women acquire
surface colonization at delivery, and without intrapartum
antibiotic therapy, about 1% of colonized full-term infants
develop EONS. GBS disease remains the leading infectious
cause of morbidity and mortality among newborns in the
USA [6, 7]. The pathogenicity of GBS has been attributed
to a number of virulence factors, including lipoteichoic acid,
a thick polysaccharide capsule, capsular sialic acid, and the
enzyme C5a-ase, which inhibits neutrophil accumulation at
the site of infection [8].
Culture screening of both the vagina and rectum for GBS
during late gestation in prenatal care can detect women who
arelikelytobecolonizedwithGBSatthetimeofdeliveryand
are consequently at higher risk of perinatal transmission of
the germ [9]. Numerous studies have documented that the
accuracy of prenatal screening cultures in identifying intra-
partum colonization status can be enhanced by careful at-
tention to the timing of cultures, the anatomic sites swabbed,
and the precise microbiologic methods used for culture and
detection of organisms [10]. Swabbing both the lower vagina
and rectum (i.e., through the anal sphincter) increases the
yield substantially compared with sampling the cervix or
sampling the vagina without also swabbing the rectum [11].
Although swabbing both sites is recommended and the use
of two swabs can be justiﬁed, both swabs should be placed in
a single broth culture medium because the site of isolation
is not important for clinical management and laboratory
costs can thereby be minimized. Because vaginal and rectal
swabs are likely to yield diverse bacteria, the use of selective
enrichmentbrothisrecommendedtomaximize theisolation
of GBS and avoid overgrowth of other organisms.
Following enrichment, the conventional means for iden-
tifying GBS is through isolation on subculture to blood
agar plates and presumptive identiﬁcation by the CAMP test
[12] or serologic identiﬁcation using latex agglutination with
groupBstreptococcalantisera[13].Often,manylaboratories
direct inoculate the sample on a solid agar medium upon
receipt of the swab in the laboratory in order to speed the
identiﬁcation of GBS; however, this procedure should never
be used as a substitute for a selective broth medium, because
as many as 50% of women who are GBS carriers have false-
negative culture results [14]. More recently, chromogenic
agars that undergo color change in the presence of beta-
hemolytic colonies of GBS have become available [15, 16].
As with pigmented enrichment broths, these chromogenic
agars can facilitate detection of beta-hemolytic GBS, but the
majority will not detect nonhemolytic strains.
Great eﬀorts in the ﬁeld of GBS disease prevention are
devoted to the development of a rapid, sensitive, and inex-
pensive test to detect GBS colonization in women who arrive
at the hospital already in labor. A number of commercially
developed assays for GBS antigen have been tested and
proved to have high sensitivity for detecting heavy GBS vag-
inal colonization, but the overall sensitivity is much lower
than that of selective broth culture [17, 18]. Since approx-
imately 15% of cases of neonatal GBS sepsis occur when
mothers have only light GBS colonization, immunoassays do
not currently have adequate sensitivity to be clinically useful
[19]. In addition more rapid techniques for identifying GBS
directly from enrichment broth, or after subculture, have
been developed, including DNA probes [20–23]a n dn u c l e i c
acid ampliﬁcation tests (NAAT) such as polymerase chain
reaction [24, 25]. These studies demonstrate the high sen-
sitivity, speciﬁcity, positive, and negative predictive value of
thesetechniques,buttheirimplementationislimitedbecause
the enrichment phase is required.
Published studies on the performance of commercially
available NAAT on nonenriched samples have demonstrated
diﬀerent levels of sensitivities (range: 62.5–98.5%) and spec-
iﬁcities (range: 64.5–99.6%) when compared with the gold
standard of enrichment followed by subculture [26–35]. The
sensitivity of NAAT for GBS increases to 92.5–100.0% with
the use of an enrichment step before testing the sample
[24,25,35].Theuseofanenrichmentsteplengthensthetime
to obtain a ﬁnal result; however, for antenatal testing, the
accuracy of results is much more important than timeliness.
Despite the availability of NAAT for GBS, utility of such
assays in the intrapartum setting remains limited. Although
a highly sensitive and speciﬁc test with rapid turnaround
time could be used to assess intrapartum GBS colonization
and therefore obviate the need for antenatal screening, data
on currently available assays do not support their use in
replacement of antenatal culture or risk-based assessment of
women with unknown GBS status on admission for labor.
The additional time required for enrichment of samples
makes it not feasible for intrapartum testing, and the sensi-
tivity of assays in the absence of enrichment is not adequate
in comparison to culture. In addition, concerns remain
regardingreal-worldturnaroundtime,testcomplexity,avail-
ability of testing at all times, staﬃng requirements, and costs.
In settings that can perform NAAT, such tests might prove
useful for the limited circumstance of a woman at term with
unknown colonization status and no other risk factors. Even
optimal NAAT would have drawbacks in the intrapartum
setting, including a delay in administration of antibiotics
while waiting for the result and no antimicrobial suscepti-
bility testing for penicillin-allergic women [36]. Other rapid
tests in addition to NAAT have been developed to detect
GBS rapidly from nonenriched samples, including optical
immunoassays and enzyme immunoassays; however, none
is suﬃciently sensitive when used on a direct specimen to
detect GBS colonization reliably in the intrapartum setting
[17, 27, 37–39].
When perinatal GBS screening is not performed and
intrapartumantibioticprophylaxisisnotadministered,new-
borns can develop systemic signs and symptoms of infection.
Cases of early-onset GBS sepsis continue to occur despite
routine screening for GBS and incur signiﬁcant morbidity
and mortality. Microbiological diagnosis of neonatal sepsis
is traditionally performed with blood cultures (BC), and
despite its function as a gold standard, it suﬀers from the
disadvantages of low sensitivity and reporting delay of 24–
72h. The diagnostic capabilities of blood culture systems
have improved over the last decade with the advent of auto-
mated continuous blood culture monitoring systems. Al-
though these systems can save time, subcultures are required
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pathogen identiﬁcation. In addition, neonatal blood cultures
present unique problems with regard to reliability. Fastid-
ious organisms, maternal antibiotic treatment, and small
specimen volumes decrease the sensitivity of blood cultures.
Furthermore, contamination of BC by skin microbiota such
as coagulase-negative staphylococci (CONS) may be prob-
lematic. Inadequate sample volume is a frequent problem in
children and neonates, and the sensitivity of blood culture
improves with increased blood volume [40–42]. In neonates,
where low-grade bacteremia is common (<4 colony-forming
units/mL),atleast1mLisnecessaryforacceptablesensitivity
a n ds p e c i ﬁ c i t yo fB Ct e s t i n g[ 43].
To overcome the BC limitations, rapid assays have been
developed to expedite detection of GBS in newborn urine
and blood and facilitate initiation of speciﬁc antibiotic ther-
apy. These tests include the rapid detection of GBS antigen
with latex agglutination or DNA ﬁnding with ampliﬁcation
techniques. Many studies evaluated the utility of latex parti-
cle agglutination testing for antigen in the diagnosis of GBS
sepsis in newborns. All authors demonstrated that sensitivity
of these tests varies signiﬁcantly among the commercially
available assays for the detection of GBS antigenuria when
concentrated and unconcentrated urine specimens were
tested. These diﬀerences in sensitivity may aﬀect the abilities
of clinicians to accurately diagnose GBS sepsis before culture
results are available [44–48].
In our review of the published literature, we found only
one published study reporting the results of molecular tech-
niques for direct detection of GBS DNA in newborns with
suspicion of early-onset sepsis. Golden et al. evaluated a hy-
bridization probe polymerase chain reaction (PCR) assay to
detect GBS-speciﬁc cfb gene target DNA sequence in blood
specimens [49]. Both sensitivity and speciﬁcity of the real-
time PCR assay were 100%. The assay demonstrated 100%
speciﬁcity when tested against 26 non-GBS bacteria. This
method is capable of detecting as few as approximately 100
copies or 10pg of GBS genomic DNA. This real-time PCR
method is rapid, sensitive, and speciﬁc for the detection of
GBS in neonatal blood samples and holds great promise in
its utility in the diagnostic laboratory.
2.2. Escherichia coli Early-Onset Neonatal Sepsis. Intrapar-
tumantibiotics havereducedtheincidence ofneonatal early-
onset GBS disease. Some surveillance data suggest that this
success may be at the cost of increasing rates of non-GBS
infection, especially in premature neonates. Lin et al. and
Stoll et al. in their recent studies [50, 51]c o n ﬁ r m e da ni n -
creaseinEONScausedbyE.coli,asnotedpreviously[52,53].
Inaddition,infantswithearly-onsetE.colisepsisshowapoor
outcome with high mortality and a third of the survivors
manifesting neurodevelopmental impairment [54].
EONS with E. coli often presents at delivery and is char-
acterized by bacteremia with or without meningitis. Septic
shock due to endotoxemia may be a presenting sign. Alterna-
tively, neonates may become colonized with E. coli at birth or
through contact with colonized caregivers while in the NICU
and may develop infection later. Environmental sources in-
cludeventilationsystemsandstorageshelves[55].Outbreaks
of both enteropathogenic and nonenteropathogenic strains
of E. coli have been described in the NICU [55–57].
An u m b e ro fE. coli virulence factors have been identiﬁed
and linked to neonatal sepsis, including the K1 capsule,
ﬁmbriae,hemolysin,roughlipopolysaccharide,Ibe(invasion
of brain endothelium) proteins, cytotoxic necrotizing factor
1, and a cluster of genes present in pathogenic but not in
avirulent strains of E. coli C5, a strain commonly implicated
in neonatal meningitis. In a study by Friesen and Cho, E.
coli isolates from term infants with sepsis were more likely
to express multiple virulence factors than were those from
preterm infants with sepsis implying that bacterial factors
contribute to the infectivity of E. coli in term infants while
host factors contribute to disease susceptibility in preterm
neonates [58].
Inprematureinfant,thebacterialepidemiologyhascom-
pletely changed during the last10 yearswithE.coli becoming
largely predominant, and with most E. coli infections being
caused by strains showing ampicillin resistance [59]. Schu-
chat et al. demonstrated that no deaths occurred among
susceptible E. coli infections, whereas 41% of ampicillin-
resistant E. coli infections were fatal. Ninety-one percent of
infants who developed ampicillin-resistant E. coli infections
werepreterm,and59%oftheseinfantswereborntomothers
who had received intrapartum antibiotic prophylaxis. These
data suggest caution regarding the use of ampicillin instead
of penicillin for GBS prophylaxis [59].
Prevention of E. coli sepsis, especially among preterm
infants, remains a challenge. Despite the data shown on in-
creasing incidence for E. coli EONS, no prevention or screen-
ing programs are possible during pregnancy and at delivery.
Sepsis caused by E. coli can be only diagnosed on a clinical
basis and with the support of BC.
2.3. Haemophilus Inﬂuenzae Early-Onset Neonatal Sepsis.
Haemophilus inﬂuenzae may be vertically transferred from
mother to infant at the time of delivery and occasionally
causes EONS in preterm infants. H. inﬂuenzae accounted for
8.3% of EONS cases in the most recent National Institute
Child Health and Human Development (NICHD) survey
[52]. Most cases involve nontypable strains, with fewer
than 10% caused by H. inﬂuenzae type b, presumably due
to maternal immunity to the latter. The presentation of
H. inﬂuenzae sepsis in preterm neonates is generally quite
fulminant and often includes pneumonia simulating severe
respiratory distress syndrome. Mortality has been reported
as high as 90% [58].
2.4. Listeria monocytogenes Early-Onset Neonatal Sepsis.
Listeria monocytogenes is a well-known and well-studied
neonatal pathogen. An American study published in 1991
reported a rate of isolation of L. monocytogenes in preterm
infants early-onset sepsis less than 5%, and the incidence of
L. monocytogenes sepsis in neonates was approximately 13
per 100,000 live births in the USA as well as in Europe [60].
The vast majority of cases represent perinatal transmission,
although nosocomial transmission has been reported [61,
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of Listeria infections have been reported [51, 63–65]. Lis-
teria infection during pregnancy may result in miscarriage,
stillbirth, or chorioamnionitis, often with placental abscesses
[43]. Infection occurring after the ﬁfth month of pregnancy
commonly leads to premature labor and delivery, with up
to 70% of cases delivering at less than 35-week gestation
[66]. Listeria may infect the fetus through the ascending or
hematogenous route, often leading to signs of severe sepsis at
delivery [67]. In contrast to nearly all other organisms caus-
ing neonatal sepsis, Listeria is an intracellular pathogen and
primarily targets cells of the monocyte-macrophage lineage.
Impaired cell-mediated immunity predisposes the very-low-
birth-weight (VLBW) infant to overwhelming infection with
this intracellular pathogen [68].
Listeriosis should be considered if there has been mater-
nal febrile illness or another clinical pointer. Amniotic ﬂuid,
placental tissues, maternal blood, and vaginal secretions,
neonatal blood and CSF should be cultured in addition to
the routine infection screening swabs.
Prenatal screening programs for Listeria monocytogenes
colonization are not routinely performed, but it is recom-
mended in cases of suspicion [69]. In such cases, our labo-
ratory cultures the vaginal swabs and performs a subculture
after enrichment in Tryptic Soy Broth with incubation at
4◦C for 7 days. Serology is of little use because of cross-
reactivity with other Gram-positive bacteria, and culture-
positive patients often have no detectable antibodies [70].
3.Late-OnsetNeonatalSepsis
Late-onset septicemia is caused by organisms thriving in
the external environment of the home or the hospital. The
infection is often transmitted through the hands of the
care providers. The onset of symptoms is usually delayed
beyond 72 hours after birth, and the presentation is that of
septicemia,pneumonia,ormeningitis.Theassociatedfactors
of late-onset sepsis include low birth weight, low gestational
age, mechanical ventilation, total parenteral nutrition and
its duration, previous antimicrobial exposure [71], lack of
breastfeeding, superﬁcial infections (pyoderma, umbilical
sepsis), aspiration of feeds, disruption of skin integrity with
needle pricks, and the use of intravenous ﬂuids or central
venous catheter [71]. These factors enhance the chances of
entry of organisms into the bloodstream of the neonates
whose immune defences are poor as compared to older chil-
dren and adults. In addition, poor hand hygiene is associated
with LONS and improving hand hygiene seems to be a
method to prevent LONS [72].
In the most recent NICHD surveys, LONS is over 10
times more common than EONS in VLBW infants. The
NICHD reported a 21% incidence of blood-culture-proven
LONS among VLBW infants [73]. The incidence is higher
among infants of <25-week gestation, with 46% of these
infants suﬀering from LONS [73]. Infants who develop late-
onset sepsis have a signiﬁcantly prolonged hospital stay.
They are signiﬁcantly more likely to die than those who are
uninfected,especiallyiftheyareinfectedwithGram-negative
organisms (36%) or fungi (32%) [73].
The most frequent microorganisms involved in LONS
are Coagulase-negative staphylococci (CoNS), Enterobacte-
riaceae, including Escherichia coli and Klebsiella pneumoniae,
and Acinetobacter baumannii [74].
3.1. Coagulase-Negative Staphylococci Late-Onset Neonatal
Sepsis. CoNSaretheetiologicagentsofthemajorityofnoso-
comial infections in neonates [73]. Although CoNS are com-
mon commensal organisms with little pathogenicity in im-
munocompetent hosts, premature neonates are particularly
susceptible to invasive infection [19]. The ﬁrst step in the
pathogenicity of CoNS involves adherence of the bacteria to
skin, mucosal surfaces, or indwelling artiﬁcial devices, such
as intravascular catheters and central nervous system shunts,
which are commonly used in preterm infants. Adherence
of CoNS is facilitated by a capsular polysaccharide adhesin
consisting of poly-N-succinyl glucosamine [75, 76]. Once
adherence and colonization have been established, some
CoNS produce an exopolysaccharide “slime,” which allows
the organisms to form a bioﬁlm and evade host defense
mechanisms and antibiotic activity. The ability of CoNS to
produce slime and bioﬁlms has been linked to increased
virulence in preterm infants [77]. Mixed-species bioﬁlms of
S. epidermidis and Candida albicans may be particularly
pathogenic to preterm infants. A recent report demonstrated
that the slime produced by S. epidermidis inhibited the
penetration of ﬂuconazole into mixed fungal and bacterial
bioﬁlms and, conversely, that C. albicans protected staphy-
lococci from the action of vancomycin [78]. The major
speciesinvolvedinneonatalinfectionisS.epidermidis,whic h
accounts for approximately 60 to 93% of CoNS blood-
stream infection [77]. The majority of CoNS colonization
is nosocomially acquired, predominantly from the hands of
health care workers. Neonates with intravascular catheters,
particularly those with central vascular catheters which
remain in place for prolonged periods, are at high risk for
CoNS bacteremia. In one small study, it was found that the
administration of two doses of cefazolin during removal of
thecentralvenouscatheterwasassociatedwithareductionin
postcatheter removal of CoNS sepsis [79]. This intervention
requires further study before it can be routinely recom-
mended.
Another signiﬁcant risk factor for CoNS septicemia is the
administration of intravenous lipid infusions, which provide
a growth medium for the organism [80, 81]. Sepsis with
CoNS is often indolent rather than fulminant, although
fatalities have been reported [82].
3.2. Enterobacteriaceae Late-Onset Sepsis. Gram-negative en-
tericorganismsoftheEnterobacteriaceaefamilyarecommon
inhabitants of the neonatal intestine which may cause noso-
comial sepsis. Similarly to what is described for E. coli,
these organisms are surrounded by a capsule and ﬁmbriae
that contribute to their virulence in neonates. This capsular
polysaccharide prevents activation of the alternative com-
plement system protecting the bacteria from opsonization,
phagocytosis, and bacteriolysis [83]. These organisms spread
rapidly in the neonatal intensive care unit (NICU), and
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intheliterature.Epidemiologicstudieshaveshownthatmost
nursery outbreaks are due to a limited number of clones
transmitted from patient to patient on the hands of health
care workers. Contaminated breast milk or equipment used
for breast milk expression have both been suggested as
sources for Gram-negative colonisation and invasive disease
[84, 85]. In addition, the transmission of nosocomial patho-
gens can occur through contaminated powdered infant for-
mula, which recently caused a fatal case of Enterobacter saka-
zakiisepsis andmeningitis inapreterminfant[86].Intensive
eﬀorts at reducing nosocomial transmission of members of
the Enterobacteriaceae have successfully eradicated coloniza-
tion and disease with virulent enteric strains, although in
some cases closing a NICU to new admissions has been
deemed necessary to prevent life-threatening infections dur-
ing outbreaks.
Parm et al. in their recent study, proposed a strategy
to prevent LONS with Gram-negatives through the perfor-
mance of surveillance cultures. Although ineﬃcient for the
prediction of Gram-negative late-onset sepsis in neonatal
intensive care units, routine mucosal cultures screening for
speciﬁc organisms in an outbreak (e.g., Klebsiella spp., E.
coli,Stenotrophomonasspp.andPseudomonasspp.)mayoﬀer
an opportunity to improve infection control measures and
enable timely initiation of appropriate antibiotic therapy
[87].
3.3.AcinetobacterbaumanniiLate-OnsetNeonatalSepsis. Ac-
inetobacter baumannii is one of the emerging causes of
neonatal sepsis [88]. A. baumannii can persist in the hospital
environment and has the ability to develop resistance to a
majority of antimicrobials [89]. Carbapenem resistance is
especially dangerous as almost no options are left for treat-
ment, particularly in neonates [90]. Urgent steps need to be
taken to prevent the spread of such resistant organisms in the
neonatal intensive care units.
4.AntibioticResistance inNeonatalSetting
Nowadays antibiotic resistance is a widespread global prob-
lem. Methicillin-resistant staphylococci, extended β-lactam-
ase (ESBL), and multidrug-resistant Gram-negative organ-
isms represent the principal concern for clinicians who have
to ﬁght against infections. A recent study from Taiwan re-
portedthat41%ofneonateswerecolonizedwithmethicillin-
resistant Staphylococcus aureus (MRSA) in the NICU and
estimated that 26% will develop invasive infections [91].
A similar infection rate of 21% was also found in a study
in the USA [92]. Neonates with invasive MRSA infection
have lower birth weight, are more likely to receive parenteral
nutrition,orhaveanindwellingpercutaneouscentralvenous
catheterand/oranendotrachealtubeatthetimeofinfection.
Colonization with community-acquired MRSA (CA-MRSA)
also emerged recently [93, 94]. CA-MRSA is acquired usually
through skin contact with colonized adults, but breast milk
can also be a vector [95]. Primary CA-MRSA infections are
likely to be localized to skin and soft tissues, but bacteremia
and life-threatening systemic infections may occur, often
associated with invasive device use [96–98].
Among Gram-negative microorganism, a recent study
reportedthatalloftheKlebsiella andEnterobacterwhichwere
the most common cause of bacterial sepsis were completely
resistant to current empirical treatment protocol (ampi-
cillin + gentamicin) [99]. These are the ﬁrst-line treatment
for sepsis according to the World Health Organization
(WHO) recommendation. Gram-negative bacteria acquired
the resistance to beta-lactam antibiotics: the prevalence of
extended-spectrum-betalactamase(ESBL)variesindiﬀerent
regions. India reports very high percentage of isolation of
ESBL enterobacteria in diﬀerent years: 87% in 2003 and 58%
in 2007 [100]; in Europe the prevalence is lower, but in some
regions of south Italy authors report a rate of up to 27%
[101]. The risk factors for the acquisition of ESBL producing
Enterobacteria were identiﬁed as birth weight, gestational
age, antimicrobial treatment, and duration of hospital stay
[102]. This ﬁnding conﬁrms older publications [103–105].
5.DiagnosisofNeonatal Sepsis
5.1. Blood Cultures. As mentioned above, the isolation of
microorganisms from blood is the standard method used
to diagnose sepsis in the newborn infant [106]. Important
procedures to improve the sensitivity and speciﬁcity of blood
cultures include proper skin disinfection before collection,
culturing early in the septic episode, taking an appropriate
volume of blood per culture, and, if collecting through an
existing intravenous device, ensuring that a peripheral cul-
tureisalsocollectedand,wherepractical,morethanonebot-
tleperepisode.Thisisnotalwaysfeasibleinaverytinyinfant.
Despite the fact that the blood culture is the gold stand-
ard in the diagnosis of neonatal sepsis, it suﬀers from the
disadvantages of low sensitivity and reporting delay of 24–
72h. The diagnostic capabilities of blood culture systems
have improved over the last decade with the advent of auto-
mated continuous blood culture monitoring systems. Al-
though they can save time, subcultures are required for
speciﬁc biochemical or other assays, ultimately needed for
pathogen identiﬁcation.
5.2. Blood Volume. There are few clinical data on the eﬀect
of blood volume alone on blood culture outcome in new-
borns. In the UK, reported volumes per culture drawn vary
from 0.3mL to 0.66mL, all well under the lower limit of
1mL recommended by paediatric blood culture bottle man-
ufacturers [107–109].
The issue of blood volume drawn and blood-broth dilu-
tionstillremainunsolved.Evidencethatsupportsthelimited
impact of the blood volume drawn comes from studies on
quantitative blood cultures obtained from septic newborn
in 1970s; results indicated that 80% of these patients were
infected with high loads of Escherichia coli and since then
it has traditionally been thought unnecessary to draw more
than small amounts of blood [110]. Conversely, a study
on infants from 2 months to 18 months of age (mean 15
months) admitted to the paediatric emergency department
with suspicion of sepsis underlines the importance of in-
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11.5mL blood from 300 children. Then, 10mL was divided
into one 6mL and two 2mL aliquots; each was further
divided and inoculated into aerobic and anaerobic culture
bottles. The remaining 1.5mL was used in a quantitative
culture system. In 30 signiﬁcant infection episodes, the 6mL
bleed had greater detection sensitivity at 24 hours than the
two 2mL bleeds combined, and a greater ﬁnal sensitivity
[40]. As hypothesized by Washington II and Ilstrup, bacter-
aemias with high concentrations of organisms require less
blood to be sampled than low density bacteraemias [111].
The concentration of a variety of common pathogens in
neonatal and paediatric bacteraemias has been documented
in numerous studies using quantitative culture systems
[112–117]. Despite many organisms occurring in high
concentrations, low-density bacteraemia is also recorded for
most pathogens. In a laboratory-based study, Schelonka and
colleagues [43] explored the eﬀect of small blood culture
volumes for a variety of common neonatal pathogens. A
range of blood volumes containing known concentrations
of neonatal pathogens were injected into standard paediatric
blood culture bottles. If organisms were present at densities
of <4 colony-forming units (cfu)/mL, blood volumes of
0.5mL or less had a signiﬁcantly diminished chance of de-
tecting bacteraemia. This ﬁnding did not diﬀer between
organisms. Brown and colleagues [118], however, using sim-
ilar in vitro techniques, found that placental blood seeded
with more than 10cfu/mL E. coli or group B streptococcus
required only 0.25mL blood to be consistently detected.
Dealing with the importance of maintenance of dilution
blood broth, a prospective Mexican study supports this the-
sis. Authors examined infants up to 12 months with clinical
signs and symptoms of sepsis. From the same venepuncture,
a volume of 2.2mL of blood was drawn from each infant
and divided into 2.0mL and 0.2mL aliquots and injected
into culture medium, maintaining a blood to total broth
dilution of 10%. Compared with the 2.0mL aliquot, the
0.2mL sample was found to have a sensitivity of 95% and
speciﬁcity of 99% for detection of signiﬁcant bacteraemia
[119].Thesedataagreewithadultstudiesresults,wheredilu-
tion appeared to aﬀect culture sensitivity. In adult setting,
maximal sensitivity was reported when the blood volume
was 10–20% of the total medium volume [120, 121]. Despite
this evidence, Kennaugh and colleagues found no eﬀect of
dilution between 1:10 and 1:100, using 0.5mL adult blood
seeded with low concentrations of common neonatal and
paediatric pathogens [122].
5.3. Number of Blood Cultures. There is limited information
to guide the practitioner on the optimal number of blood
cultures that should be obtained when evaluating an infant
forsuspectedneonatalsepsis[106,123–125].Somedatahave
suggested that, in the neonatal period, multiple site blood
cultures may improve pathogen detection if bacteremia is
intermittent, if there is a low density of bacteria present in
thecirculation,ifthereisanoverdilutionofthesmallvolume
of blood obtained during a culture with the blood culture
broth, or if there is an inhibitory eﬀect of the intrapartum
antibiotic therapy administered to mothers [125]. Indeed,
several authors have suggested that multiple-site blood
c u l t u r e sm a yb em o r ee ﬃcacious in diagnosing neonatal
sepsis [123, 125–127].
In adults, taking up to three blood cultures per sepsis
episode increases the chance of detecting bacteraemia [111,
120, 128, 129] and the recommendations for older children
and adults are to obtain blood cultures from at least two sites
[125]. There are no neonatal data, as usual practice is to take
only one blood culture before starting antibiotic treatment
[130, 131]. This decreased sampling is attributed to the
smallcirculatingbloodvolumesofneonates,thepotentialfor
increased transfusion requirements, the technical diﬃculties
posed, and the possible rapid deterioration of newborns in
the setting of sepsis [132]. In children, raising the number of
blood cultures to two or three bottles, whether from one or
more sites, does increase yield [40, 41, 133].
To our knowledge, there is only one prospective and
observational study that has been performed to determine
the usefulness of two site blood cultures in the initial eval-
uation of neonates for sepsis. This study strongly indicated
that a single site blood culture with blood volume of ≥1mL
should be suﬃcient to document “true” Gram positive,
Gram negative, or fungal sepsis in neonates. All neonates
with positive cultures had the same organism with a similar
sensitivitypatternobtainedfromthetwodiﬀerentperipheral
sites. In this study, the blood cultures were obtained from
two diﬀerent peripheral sites within 15–30min of each other
in every neonate once sepsis was suspected. Since no infant
grew organisms from only one of the two sites, a single site
blood culture should be suﬃcient to document sepsis, and is
biologically plausible possibly because young children have
high-colony-count bacteremia [134], the bacterial clearance
is slower, and the bacteremia is more continuous in neonates
with sepsis than in older patients [135].
5.4. Timing to Blood Collection. In contrast with extensive
adult data on the periodicity of bacteriemia in a variety of
clinical scenarios, neonatal setting is characterized by a lack
of data on timing of blood cultures. Unfortunately, the ne-
cessity to have a prompt antibiotic coverage when the infant
shows signs of sepsis contributes to the lower rate of signifi-
cant positive blood cultures in neonates [112].
Practically, the optimal time to culture for bacteraemia is
“as early as possible” in the course of a septic episode and the
interval between repeat blood cultures does not appear to be
important [136]. Wherever feasible, BC should be obtained
before initiation of antibiotic therapy.
5.5. Time to Positivity. Ar e c e n ts t u d yw a sc o n d u c t e dt o
determine the time to positivity (TTP) of neonatal blood
cultures,toinvestigatediﬀerencesbetweenearly-onsetversus
late-onset sepsis, and nonproven versus proven sepsis, and
to examine diﬀerences in TTP by organism type using a
retrospective observational study. The TTP was recorded for
all episodes of suspected sepsis in an approximately 6.5-
year period. A total of 2916 blood cultures were collected,
of which 437 (15%) became positive. The overall TTP
was 21.33h. The diﬀerence between the median TTP in
early-onset versus late-onset sepsis was 0.83h (22.00 versus
21.17h, P = 0.75). The median TTP for Gram-negativeInternational Journal of Pediatrics 7
organisms was 11.17h, whereas the median TTP for Gram-
positiveorganismswas23.59h(P<0.001).InGram-positive
isolates, the median TTP for CoNS was 26.67h, whereas the
median TTP for non-CoNS was 12.83h (P<0.001). The
median TTP in proven sepsis was 20.17h, whereas it was
29.67h (P<0.001) in nonproven sepsis. TTP of neonatal
blood cultures was signiﬁcantly shorter for Gram-negative
organisms. Authors suggest shortening the total incubation
time of neonatal blood cultures to a maximum of 3 days.
According to results showed, authors propose to narrow
the antimicrobial spectrum to solely target Gram-positive
bacteria when the culture is still negative after 48h, and to
cease antimicrobial therapy when the culture is still negative
after 72h in clinically well infants [137].




tidis and Candida albicans, are nearly always signiﬁcant, even
in the context of a well-looking child [138]. Cultures positive
with potential pathogens that may also be contaminants are
far more diﬃcult to interpret, the most common of which
is CoNS. These results must always be interpreted in the
speciﬁc clinical context in which they are seen. Whereas
CoNS grown from a previously well child presenting from
the community are almost always a contaminant, CoNS
growing three days later from the same child after being in
hospital with an indwelling intravascular device may well be
signiﬁcant. There are no highly speciﬁc and sensitive criteria
for determining the clinical importance of CoNS isolates
based on clinical and routine microbiological parameters.
Most deﬁnitions used in adults and older children involve
the same organism being grown from at least two separate
bleeds, not taken from indwelling intravascular devices
[139]. In neonatology, usually only one blood culture is
taken before the start of antibiotic treatment, making such
deﬁnitions diﬃcult to use. Rates of contamination are
thought to be highest in neonates [120]. Cultures drawn
through indwelling intravenous devices are more likely to be
contaminated with CoNS colonising the lumen of the device,
which may not be causing systemic infection. Positive blood
cultures with higher colony counts and ﬂagging positive
within 48 hours of being drawn have been associated with
an increased likelihood of signiﬁcance, but are not absolutely
sensitive or speciﬁc, and may be aﬀected by prior antibiotic
use [140–142].
5.7. Molecular Methods. The development of pathogen de-
tection tools assisting blood cultures that oﬀer more rapid
resultsandhighersensitivityisexpectedinneonatalintensive
caretooptimizetheuseofantimicrobialagents.Infact,when
the clinician suspects neonatal infection or sepsis, blood
culture and cultures of various body sites are immediately
undertaken and administration of broad-spectrum antimi-
crobial agents is empirically started. Because of the high
risk of mortality if sepsis is left untreated, or not adequately
treated, antibiotics cannot be de-escalated if cultures are still
negative and the baby is though clinically to have infection.
As a consequence, it is necessary to continue administration
of broad-spectrum antimicrobial agents [143]. This empir-
ical practice is associated with increased development of
drug-resistant microorganisms and disturbance of intestinal
ﬂora [144, 145]. In addition, prolonged initial empirical
antimicrobial therapy may be associated with increased risk
of necrotizing enterocolitis or death among extremely low-
birth-weight neonates [146].
Molecular methods may oﬀer advantages due to the
rapidity and the small sample volume required for analysis.
These techniques, revealing the presence of microbial DNA
in the sample, are based on hybridization or ampliﬁcation.
Technical and analytical details about these methods have
been already described for adult [147] and neonatal [148]
setting and are not the object of the present review. The pur-
pose of this paper is to discuss the utility of molecular tech-
niques in the diagnosis and management of neonatal sepsis.
Considering the wide range of bacterial species causing
neonatal sepsis, a good molecular method should identify
all possible pathogens and also those at low load in a short
time. Unfortunately, published molecular techniques are not
capabletosatisfyalltheseproperties,andtheresultsobtained
often lack sensitivity. The majority of the molecular tests
described for neonatal sepsis are home made and are based
onthedetectionof16SrRNAgene,anubiquitousgenethatis
preserved in all bacterial and comprises both conserved and
variable regions [149]. The conserved regions are targeted
by universal primers to identify it as a bacterium, and the
variable region can be utilized in genus- or species-speciﬁc
assay [40, 150].
A f t e rD N Ae x t r a c t i o n ,a na m p l i ﬁ c a t i o ns t e pc a nb e
performed using diﬀerent approaches: broad-range conven-
tional PCR and multiplex PCR. The ﬁrst strategy targets the
panbacterial 16S rDNA region, through broad-range or uni-
versal PCR primers, and is useful when followed by sequenc-
ing or hybridization [151–153]. Multiplex PCR approach
utilizes multiple primer pairs for multiple targets in a single
PCR reaction, and amplicons can be detected by sequencing,
hybridization, or, more often, by ﬂuorescent probes.
These studies [145, 153–161] were conducted to analyze
the analytical performance of diﬀerent PCR technologies.
The strength of molecular methods, as expected and under-
lined, is the rapidity to detect a positive or negative result.
Depending on the diﬀerent approach of DNA isolation, PCR
employed, and detection strategy utilized, the sensitivity of
these techniques varies from 41% to 100% and speciﬁcity
has a range between 86% and 100% in comparison with BC.
With regard to positive and negative predictive values, data
shown indicate PPV ranging from 19% and 100%, whereas
NPV is always higher than 90% (range: 94%–100%).
Our experience of the molecular diagnosis of neonatal
sepsisisbasedontheemploymentofacommercialmultiplex
real-time PCR (LightCycler SeptiFast MGRADE, Roche Diag-
nostics). This test detects more than 25 bacterial and fungal
species in a single reaction, and, to our knowledge, only
two studies have published data on implementation of this
test in a neonate setting [162, 163]. In one of these study,
multiplex PCR was tested on 34 blood samples obtained
from newborns suspected to have late-onset sepsis [162].8 International Journal of Pediatrics
The second study was conducted in a paediatric hospital,
and SeptiFast test was used to diagnose sepsis in 803 chil-
dren and newborns [163]. The positivity rate for the
molecular test was higher than BC, and authors speculated
that the rapid detection of pathogens is important in
determining the course of treatment of neonatal sepsis and
that rapid conﬁrmation of negative results is also impor-
tant. Based on conﬁrmed negative results, clinicians could
promptly interrupt empiric antimicrobial therapy and avoid
unnecessary antibiotic treatment in seriously compromised
infants. Additionally, they can rapidly redirect the clinical
investigationtowardothersitesorcausesofinfection,oreven
to other disease etiologies.
Examining all published data on molecular diagnosis of
neonatal sepsis, it is important to highlight some critical
points:
(i) molecular assays may improve the detection of
pathogens causing sepsis; the positivity rate of PCR
(range from 3% to 29%) in various studies of septic
neonates is still low. The experience gained from this
study illustrates the need for changes in sample col-
lection and preparation techniques so as to improve
analytical sensitivity of the assay;
(ii) blood volume utilized for DNA isolation signiﬁcantly
varies among the mentioned studies (range: 200μL–
2mL), thus the lack of sensitivity could depend on
the limited amount of blood extracted. By increasing
the blood volume for extraction, the higher is the
quantity of DNA isolated and the easier its detec-
tion. Unfortunately, technical diﬃculties for sample
taking in newborns, especially in small, sick preterm
neonates, often limit the volume of blood obtained
[19];
(iii) cases of false-negative results are reported in patients
who are infected with pathogens that are not targeted
in the assay;
(iv) these assays are associated with a potential for false-
positive results due to contamination from bacterial
DNA, which is widespread in the environment.
False- positive results can be obtained also if DNA
from pathogens already killed by antibiotics is
present. Molecular methods merely detect microbial
“DNAaemia”;
(v) contrary to previous theories that PCR results are not
inﬂuenced by antibiotic therapy, Dutta et al. revealed
that only 12% of samples that were PCR positive
prior to the start of antibiotic therapy were positive
after 12h of therapy and none were positive after
24 or 48h following initiation of antibiotic therapy
[161];
(vi) these tests are not yet readily available in all hospitals.
In this paper, we have analyzed published data regarding
the diﬀerent microorganisms involved in EONS and LONS.
Early-onset infections are caused by organisms prevalent in
the maternal genital tract or in the delivery area. Prevention
of these infections is possible through screening programs
for maternal vaginorectal colonization, especially for the
detection of GBS colonization in the last gestational weeks.
Such programs have resulted in the reduction of GBS in-
fections in newborns but are not currently directed to the
detectionofotherpathogensinvolvedinEONS.Wespeculate
that the extension of screening programs to other pathogens
might allow the administration of speciﬁc antibiotic prophy-
laxis.Additionally,preventionshouldbepracticedforLONS,
where pathogens are transmitted from the environment sur-
rounding the neonate, both in hospital and at home. These
practices will not reduce completely the incidence of EONS
and LONS but are a strategy to control the transmission
from mother to child or from environment to neonate. Im-
provements can also be made in the microbiological diag-
nosis of neonatal sepsis, especially in optimizing the gold
standard culture and to cover its limitations with other rapid
techniques. Molecular techniques are candidates to comple-
ment blood culture methods to diagnose neonatal sepsis,
but published data underscore the cautionary stance that
should be taken when considering the use of a molecular
ampliﬁcation test for diagnosing neonatal sepsis. Further
studies are needed to deﬁne the role of molecular assays in
the identiﬁcation of septic infants, their impact on physician
management decisions regarding antibiotics, and their eﬀect
on clinical outcome.
6. Conclusion
In this paper, we analyzed data available on the diﬀerent
microorganisms involved in EONS and LONS. Early-onset
infections are caused by organisms prevalent in the maternal
genital tract or in the delivery area. Prevention of these
infections could be practiced through screening program
formothervaginorectalcolonization.Availableprogramsare
based on the detection of GBS colonization in the last ges-
tational weeks. These programs allow the reduction of GBS
infections in newborns but are not directed to the detection
of other pathogens involved in EONS. We think that the
extension of the screening program to other pathogens could
identify them and implement the administration of speciﬁc
antibiotic prophylaxis.
On the other hand, prevention should be practiced also
for LONS, where pathogens are transmitted from the envi-
ronment surrounded the neonate. Thus, prevention should
be actuate both in hospital and at home.
This possible practice will not reduce completely the
incidence of EONS and LONS but could be a strategy to con-
trol the germs transmission from mother to child or from
environment to neonate.
Improvementscouldalsobedoneinthesettingofmicro-
biological diagnosis of neonatal sepsis, either to optimize the
gold standard culture or to cover its limitations with other
rapid techniques.
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